Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
Proceeds to support continued clinical advancement of lead program, VGA039, a first-in-class antibody targeting protein S for the treatment of bleeding disorders, starting with von Willebrand disease (VWD) VGA039 is the first subcutaneous therapy, dosed…